Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Cash | 413.00 | 487.80 | 657.80 | 888.30 |
Cash Equivalents | 692.10 | - | 449.10 | - |
Short Term Investments | 909.80 | 699.80 | 2,974.90 | 393.30 |
Cashand Short Term Investments | 2,014.90 | 1,187.60 | 4,081.80 | 1,281.60 |
Accounts Receivable- Trade Net | 5,220.20 | 4,416.80 | 3,340.30 | 3,127.30 |
Total Receivables Net | 5,221.70 | 5,081.60 | 3,939.50 | 3,851.80 |
Total Inventory | 3,441.90 | 3,579.10 | 3,898.20 | 3,378.30 |
Other Current Assets Total | 822.90 | 66.50 | 269.80 | 113.50 |
Total Current Assets | 11,501.40 | 10,016.40 | 12,261.40 | 8,716.00 |
Property/ Plant/ Equipment Total- Net | 6,914.80 | 6,826.70 | 6,422.60 | 6,333.20 |
Goodwill Net | 5,266.00 | 4,804.40 | 5,364.60 | 5,346.50 |
Intangibles Net | 2,611.00 | 1,090.50 | 1,127.20 | 1,236.30 |
Long Term Investments | 1,025.70 | 1,177.90 | 934.80 | 631.20 |
Note Receivable- Long Term | 120.80 | 148.40 | 139.90 | 110.40 |
Other Long Term Assets Total | 1,841.10 | 1,692.10 | 1,544.90 | 1,511.10 |
Total Assets | 29,280.80 | 25,756.40 | 27,795.40 | 23,884.70 |
Accounts Payable | 2,126.70 | 2,125.00 | 2,137.80 | 2,205.90 |
Current Portof LT Debt/ Capital Leases | 779.10 | 94.10 | 528.60 | 912.10 |
Other Currentliabilities Total | 2,436.10 | 922.90 | 717.50 | 734.20 |
Total Current Liabilities | 5,341.90 | 5,530.70 | 7,839.40 | 7,861.30 |
Capital Lease Obligations | 25.10 | 19.80 | 16.10 | 15.10 |
Total Long Term Debt | 25.10 | 19.80 | 378.20 | 624.60 |
Total Debt | 804.20 | 1,194.90 | 4,220.90 | 4,607.60 |
Deferred Income Tax | 446.50 | 194.40 | 153.80 | 119.70 |
Minority Interest | 2,272.10 | 2,172.50 | 2,054.20 | 1,937.30 |
Other Liabilities Total | 1,365.70 | 323.20 | 370.20 | 349.50 |
Total Liabilities | 9,451.30 | 8,240.60 | 10,795.80 | 10,892.40 |
Common Stock Total | 100.60 | 101.20 | 102.40 | 102.40 |
Retained Earnings( Accumulated Deficit) | 19,728.90 | 18,144.10 | 17,313.30 | 13,201.70 |
Total Equity | 19,829.50 | 17,515.80 | 16,999.60 | 12,992.30 |
Total Liabilities Shareholders' Equity | 29,280.80 | 25,756.40 | 27,795.40 | 23,884.70 |
Total Common Shares Outstanding | 100.60 | 101.22 | 102.37 | 102.37 |
Tangible Book Valueper Share Common Eq | 118.81 | 114.81 | 102.64 | 62.61 |
Prepaid Expenses | - | 101.60 | 72.10 | 90.80 |
Property/ Plant/ Equipment Total- Gross | - | 11,329.30 | 10,328.50 | 9,958.50 |
Accumulated Depreciation Total | - | -4,502.60 | -3,905.90 | -3,625.30 |
Accrued Expenses | - | 1,307.70 | 1,141.40 | 938.20 |
Notes Payable/ Short Term Debt | - | 1,081.00 | 3,314.10 | 3,070.90 |
Long Term Debt | - | 0.00 | 362.10 | 609.50 |
Other Equity Total | - | -729.50 | -416.10 | -311.80 |
Zydus Lifesciences Dividend Zydus Lifesciences Bonus Zydus Lifesciences News Zydus Lifesciences AGM Zydus Lifesciences Rights Zydus Lifesciences Splits Zydus Lifesciences Board Meetings Zydus Lifesciences Key Metrics Zydus Lifesciences Shareholdings Zydus Lifesciences Profit Loss Zydus Lifesciences Cashflow Zydus Lifesciences Q1 Results Zydus Lifesciences Q2 Results Zydus Lifesciences Q3 Results Zydus Lifesciences Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks